Nav: Home

Combination immune therapy shows promise against Hodgkin lymphoma

December 05, 2016

The combination of two new drugs that harness the body's immune system is safe and effective, destroying most cancer cells in 64 percent of patients with recurrent Hodgkin lymphoma, according to the results of an early-phase study.

Presented Dec. 5 at the annual meeting of the American Society of Hematology in San Diego, the study in 19 patients found that the combination of brentuximab vedotin (marketed as Adcentris) and nivolumab (Opdivo) decreased tumor size or spread (achieved remission) to some degree in all patients after three months of treatment.

Researchers say the dual therapy was "generally well tolerated," with "manageable" side effects, such as itchiness and rash, and that only two patients who experienced inflammation in the lungs were withdrawn from treatment.

The multicenter clinical trial, led by a researcher at the Perlmutter Cancer Center at NYU Langone Medical Center, was conducted in patients for whom initial chemotherapy or stem cell transplantation had failed to stop cancer cell growth. The research team says its latest results extend work presented at the same meeting in 2015, which found that a similar combination, with brentuximab vedotin and ipilimumab (Yervoy), also was safe and highly active against lymphoma.

"Although our study offers reason for optimism, the results of larger, longer-term studies already underway are needed before combination immunotherapy could become the new standard of care for people whose Hodgkin lymphoma returns after initial treatment," says study lead investigator and hematologist-oncologist Catherine Diefenbach, MD. The disease, she notes, affects mostly those under age 40, with one in 10 experiencing relapse, leading to some 1,300 deaths per year. Most cases of Hodgkin lymphoma are considered curable if diagnosed and treated early.

"If further testing proves successful, such dual therapies could potentially become an alternative curative regimen for relapsed Hodgkin lymphoma," says Diefenbach, an assistant professor at NYU Langone and clinical director of lymphoma program services at the Perlmutter Cancer Center.

Diefenbach says the team's experiments were inspired by her laboratory's research in 2012, which had found that in patients with Hodgkin lymphoma, the workhorses of the immune system, or circulating T cells, showed signs of immune dysfunction that could make them less likely to be activated.

This led her and her colleagues to test whether drugs that spur the immune system to attack cancer cells, such as "checkpoint inhibitors" like nivolumab and ipilimumab, would work well with targeted chemotherapy with brentuximab vedotin, a drug known as an antibody-drug conjugate.

Like a Trojan horse, researchers say, brentuximab vedotin homes in on CD30, a protein on the surface of some Hodgkin lymphoma cells, and then delivers an attached dose of chemotherapy to destroy the cell. Nivolumab turns off an inhibitory switch, or "checkpoint," called PD1on T cell surfaces, which is known to prevent the immune system from identifying and attacking tumor cells. (ipilimumab targets a different checkpoint, called CTLA4.)

Moving forward, Diefenbach says she hopes to apply the concepts from this treatment strategy to other types of non-Hodgkin lymphoma.
-end-
Funding support for the study, known formally as the ECOG-ACRIN Cancer Research Group, was provided by National Cancer Institute grants R01 CA180820, R01 CA180794, R01 CA180864, R01 CA180795, R01 CA180802, R01 CA180816, R01 180799, and R01 CA180790.

Besides Diefenbach, other study investigators involved in this research are Fangxin Hong, MD, at the Dana Farber Cancer Institute in Boston; Kevin David, MD, at Rutgers Cancer Institute of New Jersey; Jonathon Cohen, MD, at Emory University in Atlanta; Michael Robertson, MD, at Indiana University Hospital in Indianapolis; Ranjana Advani, MD, at Stanford University in California; Neil Palmisiano, MD, at Penn State Milton S. Hershey Cancer Center; Richard Ambinder, MD, at Johns Hopkins Kimmel Cancer Center in Baltimore; Brad Kahl, MD, at Washington University in St. Louis, Mo.; and Stephen Ansell, MD, at the Mayo Clinic in Rochester, Minn.

Media Inquiries:
David March
212-404-3528
david.march@nyumc.org

NYU Langone Medical Center / New York University School of Medicine

Related Immune System Articles:

Memory training for the immune system
The immune system will memorize the pathogen after an infection and can therefore react promptly after reinfection with the same pathogen.
Immune system may have another job -- combatting depression
An inflammatory autoimmune response within the central nervous system similar to one linked to neurodegenerative diseases such as multiple sclerosis (MS) has also been found in the spinal fluid of healthy people, according to a new Yale-led study comparing immune system cells in the spinal fluid of MS patients and healthy subjects.
COVID-19: Immune system derails
Contrary to what has been generally assumed so far, a severe course of COVID-19 does not solely result in a strong immune reaction - rather, the immune response is caught in a continuous loop of activation and inhibition.
Immune cell steroids help tumours suppress the immune system, offering new drug targets
Tumours found to evade the immune system by telling immune cells to produce immunosuppressive steroids.
Immune system -- Knocked off balance
Instead of protecting us, the immune system can sometimes go awry, as in the case of autoimmune diseases and allergies.
Too much salt weakens the immune system
A high-salt diet is not only bad for one's blood pressure, but also for the immune system.
Parkinson's and the immune system
Mutations in the Parkin gene are a common cause of hereditary forms of Parkinson's disease.
How an immune system regulator shifts the balance of immune cells
Researchers have provided new insight on the role of cyclic AMP (cAMP) in regulating the immune response.
Immune system upgrade
Theoretically, our immune system could detect and kill cancer cells.
Using the immune system as a defence against cancer
Research published today in the British Journal of Cancer has found that a naturally occurring molecule and a component of the immune system that can successfully target and kill cancer cells, can also encourage immunity against cancer resurgence.
More Immune System News and Immune System Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Listen Again: The Power Of Spaces
How do spaces shape the human experience? In what ways do our rooms, homes, and buildings give us meaning and purpose? This hour, TED speakers explore the power of the spaces we make and inhabit. Guests include architect Michael Murphy, musician David Byrne, artist Es Devlin, and architect Siamak Hariri.
Now Playing: Science for the People

#576 Science Communication in Creative Places
When you think of science communication, you might think of TED talks or museum talks or video talks, or... people giving lectures. It's a lot of people talking. But there's more to sci comm than that. This week host Bethany Brookshire talks to three people who have looked at science communication in places you might not expect it. We'll speak with Mauna Dasari, a graduate student at Notre Dame, about making mammals into a March Madness match. We'll talk with Sarah Garner, director of the Pathologists Assistant Program at Tulane University School of Medicine, who takes pathology instruction out of...
Now Playing: Radiolab

What If?
There's plenty of speculation about what Donald Trump might do in the wake of the election. Would he dispute the results if he loses? Would he simply refuse to leave office, or even try to use the military to maintain control? Last summer, Rosa Brooks got together a team of experts and political operatives from both sides of the aisle to ask a slightly different question. Rather than arguing about whether he'd do those things, they dug into what exactly would happen if he did. Part war game part choose your own adventure, Rosa's Transition Integrity Project doesn't give us any predictions, and it isn't a referendum on Trump. Instead, it's a deeply illuminating stress test on our laws, our institutions, and on the commitment to democracy written into the constitution. This episode was reported by Bethel Habte, with help from Tracie Hunte, and produced by Bethel Habte. Jeremy Bloom provided original music. Support Radiolab by becoming a member today at Radiolab.org/donate.     You can read The Transition Integrity Project's report here.